| Identification | Back Directory | [Name]
ADENYLOSUCCINIC ACID | [CAS]
19046-78-7 | [Synonyms]
C03794
Aspartyl-AMP
aspartyl adenylate
Adenylsuccinic acid
adenylosuccnic acid
ADENYLOSUCCINIC ACID
ADENYLOSUCCINIC ACID HYDRATE
adenylosuccinic acid free acid
L-Aspartic acid 4-(5'-adenylyl) ester
N-[9-(5-O-Phosphono-β-D-ribofuranosyl)-9H-purin-6-yl]-L-aspartic acid
L-Aspartic acid, N-[9-(5-O-phosphono-b-D-ribofuranosyl)-9H-purin-6-yl]-
L-Aspartic acid, N-[9-(5-O-phosphono-β-D-ribofuranosyl)-9H-purin-6-yl]-
2-[[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid
(S)-2-((9-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)Methyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)aMino)succinic acid | [Molecular Formula]
C14H18N5O11P | [MDL Number]
MFCD00082508 | [MOL File]
19046-78-7.mol | [Molecular Weight]
463.29 |
| Chemical Properties | Back Directory | [Boiling point ]
921.9±75.0 °C(Predicted) | [density ]
2.19±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C | [solubility ]
DMF: 20 mg/ml
DMSO: 20 mg/ml
Ethanol: Partially solublePBS (pH 7.2): 10 mg/ml | [form ]
powder | [pka]
1.86±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
OFBHPPMPBOJXRT-VWJPMABRSA-N | [SMILES]
O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(O)=O)n2cnc3c(N[C@@H](CC(O)=O)C(O)=O)ncnc23 |
| Hazard Information | Back Directory | [Uses]
Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid has the potential for the study of duchenne muscular dystrophy(DMD)[1]. | [Definition]
ChEBI: The N6-(1,2-dicarboxyethyl) derivative of adenosine 5'-monophosphate. | [in vivo]
Adenylosuccinic acid (oral administration; 3-3000 μg/mL; 6 weeks) significantly improves the features of murine DMD, it decreases the number of centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca2+?content of mdx tibialis anterior[1]. | Animal Model: | C57Bl/10ScSn (normal wild-type strain; Con)?and C57Bl/10mdx?(mdx) mice[1] | | Dosage: | 3?μg/mL, 30?μg/mL, 300?μg/mL, 3000 μg/mL | | Administration: | 3?μg/mL for 3 days and 30?μg/mL for the next 4 days, and 300?μg/mL for one week, and then 3000?μg/mL for 6 weeks | | Result: | Ameliorated the symptoms of murine duchenne muscular dystrophy.
|
| [IC 50]
Human Endogenous Metabolite | [References]
[1] Timpani CA, et al. Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy.Sci Rep. 2020 Jan 24;10(1):1125. DOI:10.1038/s41598-020-57610-w |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList1701258/0_EN.htm |
|